Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis

Huggins, 2002, Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, J Urol, 168, 9 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799 Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 Parker, 2020, Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 31, 1119, 10.1016/j.annonc.2020.06.011 Wang, 2021, Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis, JAMA Oncol, 7, 412, 10.1001/jamaoncol.2020.6973 Sathianathen, 2019, A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer, Eur Urol Oncol, 2, 649, 10.1016/j.euo.2019.01.004 Ramamurthy, 2019, Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer, Urol Oncol, 37, 688, 10.1016/j.urolonc.2019.05.017 Perlmutter, 2007, Androgen deprivation therapy in the treatment of advanced prostate cancer, Rev Urol, 9 Suppl 1, S3 Klotz, 2008, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, BJU Int, 102, 1531, 10.1111/j.1464-410X.2008.08183.x Beth Woods Sanders, 2016, Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine [published correction appears in JAMA. 2016;316(18):1924], JAMA, 316, 1093, 10.1001/jama.2016.12195 Chi, 2018, Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial, Lancet Oncol, 19, 194, 10.1016/S1470-2045(17)30911-7 Lloyd, 2015, Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: a survey capturing experiences from a diverse sample of UK patients, Value Health, 18, 1152, 10.1016/j.jval.2015.08.012 Agarwal, 2019, Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study, Lancet Oncol, 20, 1518, 10.1016/S1470-2045(19)30620-5 Morgans, 2018, Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer, J Clin Oncol, 36, 1088, 10.1200/JCO.2017.75.3335 Dias, 2018 Lunn, 2000, WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility, Stat Comput, 10, 325, 10.1023/A:1008929526011 Neumann, 2014, Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold, N Engl J Med, 371, 796, 10.1056/NEJMp1405158 Sullivan, 2015, Design, implementation, and first-year outcomes of a value-based drug formulary, J Manag Care Spec Pharm, 21, 269 Yeung, 2017, Impact of a value-based formulary on medication utilization, health services utilization, and expenditures, Med Care, 55, 191, 10.1097/MLR.0000000000000630 Establishing minimum standards in Medicaid State drug utilization review (DUR) and supporting value-based purchasing (VBP) for drugs covered in Medicaid, revising Medicaid drug rebate and third party liability (TPL) requirements. U.S. Centers for Medicare & Medicaid Services. https://www.cms.gov/newsroom/fact-sheets/establishing-minimum-standards-medicaid-state-drug-utilization-review-dur-and-supporting-value-based-0. Accessed January 6, 2021. Woods, 2018, Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness, Eur Urol Oncol, 1, 449, 10.1016/j.euo.2018.06.004